Igantet (Human Tetanus Immunoglobulin)

Igantet, a human tetanus immunoglobulin, is used in the tetanus prophylaxis pathway to provide passive immunity.

• Prevention of tetanus in susceptible individuals: delivers immediate antibodies that protect against toxin formation when vaccination status is incomplete or unknown.
• Post‑exposure prophylaxis after contaminated wounds: neutralizes tetanus toxin rapidly, reducing the risk of disease following injury.
• Tetanus prophylaxis in patients with impaired immune response: offers passive protection when active immunization may be ineffective.

• Human Tetanus Immunoglobulin consists of purified IgG antibodies derived from pooled human plasma. After intramuscular injection, the antibodies circulate in the bloodstream and bind directly to tetanus neurotoxin, preventing its attachment to neuronal tissue and blocking the enzymatic activity that leads to muscle rigidity. This passive immunization provides immediate, short‑term protection while the patient’s own immune system develops active immunity through vaccination.

Igantet may be associated with a range of adverse reactions, most of which are mild and transient.

Common Side Effects

• Injection site pain: mild soreness or tenderness at the intramuscular site.
• Redness or swelling: localized erythema or edema around the injection area.
• Low‑grade fever: transient temperature rise within 24 hours.
• Headache: mild to moderate headache not requiring intervention.
• Nausea: occasional feeling of queasiness after injection.

Serious or Rare Side Effects

• Anaphylaxis: severe allergic reaction with respiratory distress, requiring immediate medical attention.
• Serum sickness: immune complex–mediated reaction causing fever, rash, arthralgia.
• Hemolysis: destruction of red blood cells leading to anemia, observed rarely.

Before using Igantet, clinicians should observe several precautionary measures to ensure patient safety.

• Allergy assessment: confirm no known hypersensitivity to human immunoglobulins or plasma products.
• Immunization status: verify patient’s tetanus vaccination history to determine need for concurrent active immunization.
• Bleeding risk: assess coagulation status, as intramuscular injection may cause hematoma in patients on anticoagulants.
• Infants and children: adjust dosing and monitor closely due to limited data in younger populations.
• Pregnancy and lactation: use only if clearly needed, because safety data are insufficient.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Igantet can interact with other medicines, mainly through immunological or pharmacodynamic mechanisms.

Major Interactions (Avoid)

• Live vaccines: concurrent administration may reduce vaccine efficacy or increase adverse events.
• Immunosuppressants: high‑dose steroids or chemotherapy may diminish the protective effect of the immunoglobulin.

Moderate Interactions (Monitor Closely)

• Anticoagulants: intramuscular injection may increase bleeding risk; monitor coagulation parameters.
• Intravenous immunoglobulin (IVIG): overlapping therapy can raise serum IgG levels, potentially causing hyperviscosity.
• Beta‑blockers: may mask signs of anaphylaxis; observe patients closely.